Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Provision For Income Taxes?

  Alexion Pharmaceuticals Inc ( ALXN ) |
2002 - 2021 (20 years)

Provision For Income Taxes is 
$71.2M (1Y -149.8% )

ALXN Stock Price & Provision For Income Taxes

Provision For Income Taxes for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Provision For Income Taxes

chevron_right 2021 $54.8M +83.2x *
( +24.8% / year avg)
chevron_left 2002 -$651.0 T
vertical_align_top Peak $397.8M +2.06x *
vertical_align_bottom Bottom -$376.2M
arrow_drop_up # Up Years 8 8 of 20
years up.
arrow_drop_down # Down Years 12
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 2002 , or -0.53x the rate relative to it's provision for income taxes over the same period.
  • If ALXN grows it's stock at the same rate as it's provision for income taxes (+24.8%/year) , it's stock price will grow +916% and hit $996.45 over the next 10 years.
  • ALXN's stock price has gone up 4 of the 8 years (+50%) it's provision for income taxes were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Provision For Income Taxes Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Provision For Income Taxes YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $54 -114.6% $108.72 -9.3%
    4/1/2020 $-376 -611.1% $119.9 5.5%
    4/1/2019 $73 -65.3% $113.68 -2.1%
    4/1/2018 $212 150.9% $116.13 18.5%
    4/1/2017 $84 -26.1% $98.03 -30.4%
    4/1/2016 $114 -71.2% $140.8 -21.9%
    4/1/2015 $397 24.3% $180.37 2.0%
    4/1/2014 $320 124.4% $176.8 91.9%
    4/1/2013 $142 0.2% $92.14 -0.8%
    4/1/2012 $142 126.6% $92.86 88.2%
    4/1/2011 $62 -134.8% $49.34 81.5%
    4/1/2010 $-180 -4506.3% $27.18 44.4%
    4/1/2009 $4 -1387.1% $18.83 27.0%
    4/1/2008 $0 -11.9% $14.82 37.1%
    4/1/2007 $0 -4.4% $10.81 22.1%
    4/1/2006 $0 -54.4% $8.86 63.5%
    4/1/2005 $0 21.4% $5.42 -8.8%
    4/1/2004 $0 -32.9% $5.94 80.8%
    4/1/2003 $-1 56.1% $3.29 -28.8%
    4/1/2002 $0 - $4.62 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • A provision for income taxes is the estimated amount that a business or individual taxpayer expects to pay in income taxes for the current year. The amount of this provision is derived by adjusting the firm's reported net income with a variety of permanent differences and temporary differences.

    For more detailed definitions, please see Investopedia.